Results 111 to 120 of about 33,638 (296)

Ruxolitinib for Myelofibrosis [PDF]

New England Journal of Medicine, 2012
Steffen, Koschmieder, Adriane, Koppelle, Hans, Seifert   +2 more
openaire   +4 more sources

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. [PDF]

Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K ...
Ali, Haris, Assad, Albert, Borate, Uma, Daver, Naval, Erickson-Viitanen, Susan, Gerds, Aaron, Goel, Swati, Hager, Steven, Hobbs, Gabriela, Holmes, Houston, Kremyanskaya, Marina, McCloskey, James, OConnell, Casey, Oh, Stephen, Palmer, Jeanne, Rampal, Raajit, Schiller, Gary, Wang, Eunice, Winton, Elliott, Yacoub, Abdulraheem, Zhou, Feng   +20 more
core   +1 more source

Janus kinase inhibitors: jackpot or potluck?

Oncology Reviews, 2012
The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat, Shripad Brahmanand Pande   +1 more
doaj   +1 more source

Effects of Splenectomy on Red-cell Production in Myelofibrosis [PDF]

, 1961
G. Wetherley‐Mein, N. F. Jones, Jack Pullan   +2 more
openalex   +1 more source

Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced‐Intensity Fludarabine, Busulfan and Anti‐T‐Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy

European Journal of Haematology, EarlyView.
ABSTRACT Fludarabine, busulfan, and anti‐T‐lymphocyte globulin (FLUBU3+ATLG) reduced‐intensity conditioning is an established preparative regimen for allogeneic haematopoietic stem cell transplantation in older patients with myeloid malignancy. We examined its modern‐day performance in 175 sequentially treated patients on our national programme ...
Chris Armstrong, Eibhlin Conneally, Catherine Flynn, Paul Browne, Mairead Ni Chonghaile, Carmel Ann Galligan, Hayley Foy‐Stones, Nicola Gardiner, Greg Lee, Nina Orfali   +9 more
wiley   +1 more source

Cord Compression by Extramedullary Hematopoiesis in Polycythemia Vera [PDF]

, 2012
A 73-year-old male with polycythemia vera and a history of prostate cancer presents to an outside hospital complaining of back pain of two months duration.
Martinez, Jose, Reale, Lisa, Zrada, Steve   +2 more
core   +1 more source

Adult Acute Megakaryoblastic Leukemia in a Mantle Cell Lymphoma Post Treatment and Auto‐Transplant

The Kaohsiung Journal of Medical Sciences, EarlyView.
Chin‐Mu Hsu, Bi‐Hua Du, Chien Hsiao, Hui‐Hua Hsiao   +3 more
wiley   +1 more source

Clinicopathologic Characteristics and Prognostic Profile of Chronic Myeloid Neoplasms With Somatic NF1 Mutations in Adult Patients

European Journal of Haematology, EarlyView.
ABSTRACT Objectives The clinicopathologic and prognostic features of somatic NF1 mutations have been well studied in pediatric myeloid neoplasms and adult acute myeloid leukemia (AML) but not in adult chronic myeloid neoplasms (CMNs), including myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and myelodysplastic/myeloproliferative ...
Hamza Tariq, Margarita Loxas, Mir B. Alikhan, Juehua Gao, Xinyan Lu, Qing Ching Chen, Yi‐Hua Chen, Jessica K. Altman, Lawrence J. Jennings, Madina Sukhanova   +9 more
wiley   +1 more source

Primary and Secondary Myelofibrosis: Its Relationship to "PNH-like Defect" [PDF]

, 1972
Chi-yen Kuo, G. Arthur Van Voolen, Alan N. Morrison   +2 more
openalex   +1 more source

Next Generation Sequencing Identifies Subgroups of Patients With Triple Negative Primary Thrombocytosis With Different Clinical Thrombotic Outcomes

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The majority of patients with essential thrombocythemia (ET) show somatic mutations of JAK2, CALR, or MPL. Around 10% of cases lack these mutations (“triple negative” ET, TN‐ET). Additionally, some patients with bona fide “primary thrombocytosis” (PT) [i.e., high platelet (PLT)‐ count with no apparent underlying causes] do not ...
Valentina Sangiorgio, Federica Mottadelli, Fabio Pagni, Fabrizio Cavalca, Giovanni Cazzaniga, Martina Venegoni, Carlo Gambacorti‐Passerini, Rocco Piazza, Elena Maria Elli   +8 more
wiley   +1 more source